Investment
Features
FeesSafety
Academy
More
Pluang+

Compare S&P Global Inc (SPGI) vs Tilray Brands Inc (TLRY) Price & Performance

S&P Global IncTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

S&P Global Inc vs Tilray Brands Inc — how do they compare? S&P Global Inc trades at $403.72 (market cap $116.50B), while Tilray Brands Inc trades at $3.64 (market cap $549.01M). The key difference: S&P Global Inc is far larger — about 212.2× Tilray Brands Inc's market cap, and S&P Global Inc pays a 0.98% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 123 Days and Tilray Brands Inc for 31 Days on average.

SPGITLRY
Market Cap
$116.50B$549.01M
Volume
1,430,7143,292,073
Sector
FinancialsHealth
52-Week High
$517.92$21.00
52-Week Low
$370.42$3.57
Typical Hold Time
123 Days31 Days
Enterprise Value
$127.99B$716.15M
Dividend Yield
0.98%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

S&P Global Inc

S&P Global (SPGI) trades at $402.73, up 1.67% with strong analyst support showing 85.7% buy ratings and a $509.50 consensus price target. The stock faces technical headwinds with bearish moving averages but maintains robust fundamentals including 30.5% net margins and consistent revenue growth from $15.3B to $16.1B projected for 2026. Recent developments include expansion into digital asset risk assessment and the acquisition of OpenZeppelin, positioning the company for AI-driven growth across its financial services divisions.

The outlook remains positive given S&P Global's dominant market position and margin expansion potential, though investors should monitor debt levels increasing to 23.3% of assets. Near-term catalysts include Q3 2026 earnings on October 27, with the stock offering 26% upside to analyst targets despite current technical weakness suggesting potential entry points near $391 support.

Tilray Brands Inc

Tilray Brands (TLRY) trades at $3.715, down 1.72% on the day, as the stock continues to face significant pressure with bearish technical signals and fundamental challenges. The company reported a substantial net loss of $2.19 billion in 2025 despite $821 million in revenue, with negative cash flow from operations of $94.6 million. Recent earnings have consistently missed expectations, and technical indicators show a bearish trend with the stock trading near key support levels.

While TLRY shows attractive valuation metrics with P/S of 0.45 and P/B of 0.34, the company faces substantial execution risks amid persistent losses and negative cash flow. Analyst sentiment remains cautious with only 25% buy ratings, though the consensus price target of $65.01 suggests significant upside potential if the company can achieve profitability and growth targets.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SPGI
50% Buy50% Sell
Avg holding period · 123 Days
TLRY
100% Buy0% Sell
Avg holding period · 31 Days

Top news

Latest headlines on both assets

About S&P Global Inc

S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.

Read more on SPGI →

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY →